Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. [electronic resource]
Producer: 20120618Description: 427-38 p. digitalISSN:- 1538-8514
- Antimetabolites -- pharmacology
- Antineoplastic Agents -- pharmacology
- Blotting, Western
- Camptothecin -- analogs & derivatives
- Cell Cycle Checkpoints -- drug effects
- Cell Line
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Checkpoint Kinase 1
- Cytarabine -- pharmacology
- DNA Breaks, Double-Stranded -- drug effects
- DNA Damage
- Deoxycytidine -- analogs & derivatives
- Dose-Response Relationship, Drug
- Drug Screening Assays, Antitumor
- Drug Synergism
- Flow Cytometry
- Humans
- Hydroxyurea -- pharmacology
- Irinotecan
- Molecular Structure
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- chemistry
- Protein Kinases -- metabolism
- Pyrazoles -- chemistry
- Pyrimidines -- chemistry
- Staurosporine -- analogs & derivatives
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.